NEURALSTEM, INC.
GERMANTOWN, MD

NEURALSTEM, INC., GERMANTOWN

Neuralstem (NASDAQ:CUR) is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need.  Our lead asset, NSI-189, is a new chemical entity in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, neuropathy associated with Type 1 and Type 2 diabetes, and stroke.  Our lead stem cell therapy candidate, NSI-566, is a spinal cord-derived neural stem cell line being tested in Amyotrophic Lateral Sclerosis (ALS), chronic spinal cord injury (cSCI), and ischemic stroke. These product candidates are based on the company’s proprietary neural stem cell technology. The company’s proprietary methodology enables the generation and commercial-scale production of regionally specific neural stem cell lines for use in therapeutic indications or drug screening. This platform enables high content screening of compound libraries for discovery of novel CNS-targeted compounds, and led to the discovery of NSI-189, our lead compound. Co-founder of Neuralstem; NIH/NINDS Staff Scientist Neuralstem’s Stem Cell Discovery Program Director and Senior Scientist since 1998; Staff Scientist at the NIH Laboratory of Molecular Biology of the National Institute of Neurological Disorders and Stroke in Bethesda; and was a NIH IRTA fellow from 1993-1996. Mr. Richard J. Daly has served as a director on Neuralstem’s board since February 2016, when he also assumed the chief executive role of Neuralstem, as President and CEO. Mr. Daly’s career of commercial pharmaceutical leadership experience spans over 25 years and encompasses strategy, sales, marketing, and operations. Prior to joining the company, he served as Managing Director of Ravine Rock Partners, LLC, a healthcare commercial performance acceleration firm where his expertise was leveraged as the Interim CCO of Catalyst Pharma until September 2015. Mr. Daly led the turnaround initiatives of Bristol-Myers Squibb – AstraZeneca Diabetes Alliance when serving as the President of the U.S. Diabetes subsidiary from 2013 through the AstraZeneca integration completion in 2014. From 2011-2013, he was a founding Partner and Board member of SagePath Partners LLC, a commercial outsourcing provider to the pharmaceutical industry which was sold to Ashfield Commercial & Medical Services in 2013. Mr. Daly was also part of the executive leadership team that executed the formation and growth of Takeda North America. During his 13-year tenure, he served as EVP, U.S., where he was responsible for new affiliates and business development for the Americas. Earlier in his career, he served as the VP of Commercial Strategy at TAP Pharmaceuticals, an Abbott Labs and Takeda joint-venture, and SVP of Marketing at Takeda North America. Mr. Daly currently also serves on the boards of Catalyst Pharmaceuticals (NASDAQ: CPRX) and Synergy Pharmaceuticals (NASDAQ: SGYP). Mr. Daly earned an M.B.A. from Northwestern University’s Kellogg Graduate School of Management and holds a B.S. in Microbiology from The University of Notre Dame. Mr. Scott V. Ogilvie has served as a director on Neuralstem’s board since February 2008. Mr. Ogilvie is currently the President of AFIN International, Inc., an international private equity and strategic advisory firm, which he founded in 2006. Prior to December 31, 2009, he was CEO of Gulf Enterprises International, Ltd, an investment and strategic advisory company with primary activities in the Middle East and North Africa. He held this position since August 2006. Mr. Ogilvie previously served as Chief Operating Officer of CIC Group, Inc., an investment manager, a position he held from 2001 to 2007. He began his career as a corporate and securities lawyer with Hill, Farrer & Burrill, and has extensive public and private corporate management and board experience in finance, real estate, and life science and technology companies. During the past five years, Mr. Ogilvie has served on the board of directors of Innovative Card Technologies, Inc. (OTCBB:INVC), Preferred Voice, Inc., (OTCBB:PRFV), GenSpera, Inc. (OTCQB: GNSZ) and Research Solutions, Inc. (OTCQB:RSSS). His expertise is in both public and private organizations regarding corporate finance, securities and compliance and international business development. Mr. William Oldaker has served on Neuralstem’s board of directors since April 2007. Mr. Oldaker is a founder and partner in the Washington, D.C. law firm of Oldaker Group LLC. Prior to founding the firm in 1993, Mr. Oldaker was a partner in the Washington office of the law firm of Manatt, Phelps and Phillips from 1987 to 1993. In 2004, Mr. Oldaker was a founder of Washington First Bank in Washington, D.C. and serves as a member of the board of directors. He previously served as a director of Century National Bank, from 1982 until its acquisition in 2001. Mr. Oldaker was appointed by President Clinton to serve as a commissioner on the National Bioethics Advisory Commission, a post he held until 2001. He is a member of the Colorado, D.C. and Iowa Bar Associations, the Bar Association for the Court of Appeals, D.C., and the Bar of the United States Supreme Court. He is also a partner in The National Group, a consulting firm. Mr. Oldaker has extensive experience with managing and developing federal government regulations and expertise in the legislative process. He also was a founding member, and has served on the board of directors of a bank for almost thirty years. Mr. Sandford D. Smith has served on Neuralstem’s board of directors since March 2014. Since December 2011, Mr. Smith has served as Founder and Chairman of Global Biolink Partners. From 1996 until 2011, Mr. Smith served in various senior and executive management positions at Genzyme Corporation (Formerly NASDAQ:GENZ), including Executive Vice President and President, International Group with responsibility for the commercial activities for Genzyme’s products outside of the U.S. Prior to joining Genzyme, Mr. Smith served from 1986 to 1996 as President and Chief Executive Officer and a Director of Repligen Corporation, a formerly publicly traded biotechnology company. Mr. Smith previously held a number of positions with Bristol-Myers Squibb Company (NYSE: BMY) from 1977 to 1986, including Vice President of Business Development and Strategic Planning for the Pharmaceutical Group. Mr. Smith currently serves as a director of Cytokynetics, Inc. (NASDAQ: CYTK) and Apricus Biosciences, Inc. (NASDAQ: APRI). Mr. Smith serves as a member of the President’s Advisory Board of Brigham and Women’s Hospital in Boston, member of the Advisory Board of Tullis Health Investors in Greenwich, Connecticut and an advisor to BioNEST Partners in New York and Paris. Mr. Smith also is the founder of Smith Scholars, a medical residency program for physicians from resource-poor nations. Mr. Smith has a history of marketing and developing of therapies targeted at rare disease or those with orphan designations as well as his general experience in the biotech industry.

KEY FACTS ABOUT NEURALSTEM, INC.

Company name
NEURALSTEM, INC.
Status
Inactive
Filed Number
F12000002389
FEI Number
52-2007292
Date of Incorporation
June 6, 2012
Home State
DE
Company Type
Foreign for Profit

CONTACTS

Website
http://neuralstem.com
Phones
(301) 366-4960

NEURALSTEM, INC. NEAR ME

Principal Address
20271 GOLDENROD LN,,
GERMANTOWN,
MD,
20876,
US
Mailing Address
9700 GREAT SENECA HIGHWAY,
ROCKVILLE,
MD,
20850

See Also

Officers and Directors

The NEURALSTEM, INC. managed by the three persons from GERMANTOWN, Germantown on following positions: Exec, Dire

Kenneth C Carter

Position
Exec Active
From
GERMANTOWN, MD, 20876

Scott Ogilvie

Position
Dire Active
From
GERMANTOWN, MD, 20876

Sandford D Smith

Position
Dire Active
From
Germantown, MD, 20876




Events

June 24, 2019
WITHDRAWAL
February 1, 2018
REINSTATEMENT
September 22, 2017
REVOKED FOR ANNUAL REPORT

Annual Reports

2019
February 25, 2019
2018
February 1, 2018